Last reviewed · How we verify
AB001
AB001 is a small molecule that targets the PD-1 receptor.
AB001 is a small molecule that targets the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | AB001 |
|---|---|
| Also known as | topical patch, AB001 |
| Sponsor | Frontier Biotechnologies Inc. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to PD-1, AB001 prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Pneumonitis
- Diarrhea
- Fatigue
Key clinical trials
- Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (PHASE1)
- Benefits of Alcoholic Hangover Medicine (NA)
- Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects (PHASE1)
- A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |